tirzepatide and anavar in SubMagna® Tirzepatide as a Potential Disease-Modifying

Share evidence-based information to dispel myths and answer common questions

Early results from the STEP UP trial were published in The Lancet Diabetes & Endocrinology in November 2025.[1] The FDAs decision fell under the Commissioners National Priority Voucher (CNPV) pilot program, a new pathway for expediting the approval of certain therapies that address critical national health priorities. Companies chosen for this program receive a voucher that entitles them to certain benefits, including improved communication with federal regulators and a faster review process

Selenoproteins in human body: focus on thyroid pathophysiology

You are not alone, Dr

Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, et al

10.1111/dom.13186 134